Harold Selick
Chairman presso MOLECULAR TEMPLATES, INC.
Patrimonio netto: 816 017 $ in data 31/03/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Dinesh Patel | M | 67 |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | 16 anni |
Eric Poma | M | 52 |
Molecular Templates OpCo, Inc.
Molecular Templates OpCo, Inc. Financial ConglomeratesFinance Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX. | 24 anni |
Samuel Saks | M | 69 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 7 anni |
David Hoffmann | M | 79 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA
Molecular Templates OpCo, Inc.
Molecular Templates OpCo, Inc. Financial ConglomeratesFinance Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX. | 7 anni |
Jason Kim | M | 49 |
Molecular Templates OpCo, Inc.
Molecular Templates OpCo, Inc. Financial ConglomeratesFinance Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX. | 14 anni |
Chaitan S. Khosla | M | 59 |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | 7 anni |
Carin M. Rollins | F | - |
Hinge Bio, Inc.
Hinge Bio, Inc. BiotechnologyHealth Technology Hinge Bio, Inc. is a holding company, which engages in the development of specific and multi-specific antibodies. The company is headquartered in Burlingame, CA. | 19 anni |
Elizabeth O'Farrell | F | 59 | 6 anni | |
William Waddill | M | 67 |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | 8 anni |
Volker Schellenberger | M | - |
Amunix, Inc.
Amunix, Inc. Pharmaceuticals: MajorHealth Technology Amunix, Inc. develops protein pharmaceuticals. It offers XTEN which is hydrophilic, unstructured, biodegradable polypeptides that impart a number of favorable properties upon the molecules to which they are attached. The company was founded by Volker Schellenberger and Willem Stemmer in 2006 and is headquartered in Mountain View, CA. | - |
Julie Grant | F | 41 |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | 3 anni |
Kevin Lalande | M | 51 |
Molecular Templates OpCo, Inc.
Molecular Templates OpCo, Inc. Financial ConglomeratesFinance Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX. | 15 anni |
Scott Morenstein | M | 48 |
Molecular Templates OpCo, Inc.
Molecular Templates OpCo, Inc. Financial ConglomeratesFinance Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX. | 7 anni |
Dominique Monnet | M | 65 | 7 anni | |
Gabriela Gruia | M | 67 | 2 anni | |
Lewis Williams | M | 74 | 7 anni | |
Christy Horgan | F | - | 7 anni | |
Corazon Sanders | M | 67 | 5 anni | |
Tiffany Davis | F | - |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | 21 anni |
Hooman Shahlavi | M | - |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | 17 anni |
Sarah O'Dowd | F | 74 | 4 anni | |
Bryan Giraudo | M | 48 | 6 anni | |
Michael Broxson | M | - |
Molecular Templates OpCo, Inc.
Molecular Templates OpCo, Inc. Financial ConglomeratesFinance Molecular Templates OpCo, Inc. provides medical services. The company is headquartered in Austin, TX. | - |
Kristen Quigley | F | 53 | 7 anni | |
Douglas Crawford | M | - |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | 15 anni |
Aaron Tward | M | - |
The University of California, San Francisco
| 2 anni |
Greg S. Yap | M | - |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | - |
William D. Unger | M | - |
Hinge Bio, Inc.
Hinge Bio, Inc. BiotechnologyHealth Technology Hinge Bio, Inc. is a holding company, which engages in the development of specific and multi-specific antibodies. The company is headquartered in Burlingame, CA. | - |
Catherine Lynch Gilliss | M | 75 |
The University of California, San Francisco
| 7 anni |
Mohammad Masjedizadeh | M | - | 7 anni | |
Suneel Gupta | M | 66 | 5 anni | |
Ashok Bhandari | M | - | 7 anni | |
Carena Spivey | F | - | - | |
Craig Ostroff | M | - | - | |
Daniel J. Capon | M | - |
Hinge Bio, Inc.
Hinge Bio, Inc. BiotechnologyHealth Technology Hinge Bio, Inc. is a holding company, which engages in the development of specific and multi-specific antibodies. The company is headquartered in Burlingame, CA. | - |
Richard Heyman | M | 66 |
Amunix, Inc.
Amunix, Inc. Pharmaceuticals: MajorHealth Technology Amunix, Inc. develops protein pharmaceuticals. It offers XTEN which is hydrophilic, unstructured, biodegradable polypeptides that impart a number of favorable properties upon the molecules to which they are attached. The company was founded by Volker Schellenberger and Willem Stemmer in 2006 and is headquartered in Mountain View, CA. | - |
Vivian Dang | F | - |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | 15 anni |
Peter D. Parker | M | 73 |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | - |
Jack S. Wadsworth | M | 84 |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | - |
Matthew M. Gosling | M | 53 | 4 anni | |
Maurizio Voi | M | - | 1 anni | |
Malcolm L. Gefter | M | - |
Hinge Bio, Inc.
Hinge Bio, Inc. BiotechnologyHealth Technology Hinge Bio, Inc. is a holding company, which engages in the development of specific and multi-specific antibodies. The company is headquartered in Burlingame, CA. | - |
Brook Byers | M | 78 |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | - |
Nicole Vitullo | F | 66 |
Hinge Bio, Inc.
Hinge Bio, Inc. BiotechnologyHealth Technology Hinge Bio, Inc. is a holding company, which engages in the development of specific and multi-specific antibodies. The company is headquartered in Burlingame, CA. | - |
Walter H. Moos | M | 69 |
Amunix, Inc.
Amunix, Inc. Pharmaceuticals: MajorHealth Technology Amunix, Inc. develops protein pharmaceuticals. It offers XTEN which is hydrophilic, unstructured, biodegradable polypeptides that impart a number of favorable properties upon the molecules to which they are attached. The company was founded by Volker Schellenberger and Willem Stemmer in 2006 and is headquartered in Mountain View, CA. | 8 anni |
Patrick Heron | M | 53 |
Amunix, Inc.
Amunix, Inc. Pharmaceuticals: MajorHealth Technology Amunix, Inc. develops protein pharmaceuticals. It offers XTEN which is hydrophilic, unstructured, biodegradable polypeptides that impart a number of favorable properties upon the molecules to which they are attached. The company was founded by Volker Schellenberger and Willem Stemmer in 2006 and is headquartered in Mountain View, CA. | - |
Robert Blazej | M | - |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | 7 anni |
James Topper | M | 62 |
Amunix, Inc.
Amunix, Inc. Pharmaceuticals: MajorHealth Technology Amunix, Inc. develops protein pharmaceuticals. It offers XTEN which is hydrophilic, unstructured, biodegradable polypeptides that impart a number of favorable properties upon the molecules to which they are attached. The company was founded by Volker Schellenberger and Willem Stemmer in 2006 and is headquartered in Mountain View, CA. | 6 anni |
Wende Hutton | F | 63 |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | - |
Daniel Swisher | M | 61 | 1 anni | |
Camille D. Samuels | F | 52 |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | - |
Lars Ekman | M | 74 |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | 17 anni |
Misha Petkevich | M | 75 |
Hinge Bio, Inc.
Hinge Bio, Inc. BiotechnologyHealth Technology Hinge Bio, Inc. is a holding company, which engages in the development of specific and multi-specific antibodies. The company is headquartered in Burlingame, CA. | - |
Jon Root | M | 64 |
Mission Bay Capital Management, Inc.
Mission Bay Capital Management, Inc. Investment ManagersFinance Mission Bay Capital Management Inc (Mission Bay Capital) is a venture capital firm founded in 2009. The firm is headquartered in San Francisco, California. | - |
Grace Kim | M | - | 1 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Augustine Lawlor | M | 67 |
Catalyst Bioscience, Inc. /Old/
Catalyst Bioscience, Inc. /Old/ Medical SpecialtiesHealth Technology Catalyst Bioscience, Inc. develops and markets catalytic biopharmaceutical products. Its technology consists of methods to identify proteases with tailor-made specificity or improved pharmacological properties. The company was founded by Charles Craik, Sandra Waugh Ruggles and Christopher Thanos in 2003 and is headquartered in South San Francisco, CA. | 17 anni |
Adam Daniel Cutler | M | 50 | 4 anni | |
Joel A. Fernandes | M | 54 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | - |
C. Payne | M | 61 |
Catalyst Bioscience, Inc. /Old/
Catalyst Bioscience, Inc. /Old/ Medical SpecialtiesHealth Technology Catalyst Bioscience, Inc. develops and markets catalytic biopharmaceutical products. Its technology consists of methods to identify proteases with tailor-made specificity or improved pharmacological properties. The company was founded by Charles Craik, Sandra Waugh Ruggles and Christopher Thanos in 2003 and is headquartered in South San Francisco, CA. | 4 anni |
Christine R. Larson | F | 71 | 3 anni | |
Edward A. Imbrogno | M | 60 | 3 anni | |
Jeff Bird | M | 63 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 16 anni |
Emily Lee Kelley | F | 66 |
Affymax Research Institute
Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a private company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | 6 anni |
Michael S. Ostrach | M | 72 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 1 anni |
Stewart M. Kroll | M | 65 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 11 anni |
Errol de Souza | M | 70 | 7 anni | |
Donald Kalkofen | M | 60 | 3 anni | |
Thomas O'Neil | M | 59 | 3 anni | |
Mark L. Smythe | M | - | 16 anni | |
Andrea Hunt | F | 64 | 6 anni | |
Natasha Hernday | F | 52 | 3 anni | |
Laura G. Hansen | M | - |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 4 anni |
Edward Williams | M | 68 | 4 anni | |
Sarah Noonberg | M | 56 | 6 anni | |
Jeffrey Landau | M | 46 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 5 anni |
Nenad Sarapa | M | - | 1 anni | |
Conrad Jordaan | M | - | 2 anni | |
Jonathan Lanfear | M | 55 | 6 anni | |
Sean McLennan | M | 54 | 4 anni | |
Lany Soesanto | F | - |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | - |
Mark D. Matteucci | M | 70 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | - |
Shlomo Yanai | M | 71 | 2 anni | |
Nassim Usman | M | 64 |
Catalyst Bioscience, Inc. /Old/
Catalyst Bioscience, Inc. /Old/ Medical SpecialtiesHealth Technology Catalyst Bioscience, Inc. develops and markets catalytic biopharmaceutical products. Its technology consists of methods to identify proteases with tailor-made specificity or improved pharmacological properties. The company was founded by Charles Craik, Sandra Waugh Ruggles and Christopher Thanos in 2003 and is headquartered in South San Francisco, CA. | 9 anni |
Cathleen Phillips Davis | F | 70 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 2 anni |
Caroline J. Krumel | F | 60 | 2 anni | |
Bruce Cozadd | M | 60 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 12 anni |
Fredrick Frank | M | 92 | 3 anni | |
George Parker | M | 85 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 13 anni |
David Gryska | M | 68 | 6 anni | |
John G. Curd | M | 78 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 4 anni |
Peter García | M | 62 | 6 anni | |
David Parkinson | M | 73 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | - |
Karen Wilson | F | 61 | 2 anni | |
George Tidmarsh | M | 64 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 4 anni |
John P. Richard | M | 66 | - | |
Asish Xavier | M | - |
Catalyst Bioscience, Inc. /Old/
Catalyst Bioscience, Inc. /Old/ Medical SpecialtiesHealth Technology Catalyst Bioscience, Inc. develops and markets catalytic biopharmaceutical products. Its technology consists of methods to identify proteases with tailor-made specificity or improved pharmacological properties. The company was founded by Charles Craik, Sandra Waugh Ruggles and Christopher Thanos in 2003 and is headquartered in South San Francisco, CA. | 9 anni |
Paul Edick | M | 67 | 3 anni | |
Jody Lindell | F | 72 | 9 anni | |
David Hirsch | M | 53 | 6 anni | |
Jami Taylor | M | - | 2 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 89 | 89.00% |
Australia | 4 | 4.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Harold Selick
- Contatti personali